{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T14:53:44Z","timestamp":1772636024416,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"35","license":[{"start":{"date-parts":[[2016,2,15]],"date-time":"2016-02-15T00:00:00Z","timestamp":1455494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2016,2,15]],"date-time":"2016-02-15T00:00:00Z","timestamp":1455494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2016,9,1]]},"DOI":"10.1038\/onc.2016.4","type":"journal-article","created":{"date-parts":[[2016,2,15]],"date-time":"2016-02-15T06:48:53Z","timestamp":1455518933000},"page":"4663-4674","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies"],"prefix":"10.1038","volume":"35","author":[{"given":"J","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E-j","family":"Yun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Kapur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R-C","family":"Pong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Authement","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T-L","family":"Cha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H-C","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Margulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Brugarolas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J-T","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,15]]},"reference":[{"key":"BFonc20164_CR1","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1056\/NEJMra043172","volume":"353","author":"HT Cohen","year":"2005","unstructured":"Cohen HT, McGovern FJ . Renal-cell carcinoma. N Engl J Med 2005; 353: 2477\u20132490.","journal-title":"N Engl J Med"},{"key":"BFonc20164_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nature12222","volume":"499","author":"Cancer Genome Atlas Research Network","year":"2013","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013; 499: 43\u201349.","journal-title":"Nature"},{"key":"BFonc20164_CR3","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/nature08672","volume":"463","author":"GL Dalgliesh","year":"2010","unstructured":"Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010; 463: 360\u2013363.","journal-title":"Nature"},{"key":"BFonc20164_CR4","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1158\/1541-7786.MCR-11-0302","volume":"9","author":"B Kucejova","year":"2011","unstructured":"Kucejova B, Pena-Llopis S, Yamasaki T, Sivanand S, Tran TA, Alexander S et al. Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma. Mol Cancer Res 2011; 9: 1255\u20131265.","journal-title":"Mol Cancer Res"},{"key":"BFonc20164_CR5","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/ng.2323","volume":"44","author":"S Pena-Llopis","year":"2012","unstructured":"Pena-Llopis S, Vega-Rubin-de-Celis S, Liao A, Leng N, Pavia-Jimenez A, Wang S et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet 2012; 44: 751\u2013759.","journal-title":"Nat Genet"},{"key":"BFonc20164_CR6","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/ng.2699","volume":"45","author":"Y Sato","year":"2013","unstructured":"Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet 2013; 45: 860\u2013867.","journal-title":"Nat Genet"},{"key":"BFonc20164_CR7","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/nature09639","volume":"469","author":"I Varela","year":"2011","unstructured":"Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P et al. Exome sequencing identifies frequent mutation of the SWI\/SNF complex gene PBRM1 in renal carcinoma. Nature 2011; 469: 539\u2013542.","journal-title":"Nature"},{"key":"BFonc20164_CR8","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.eururo.2013.07.031","volume":"65","author":"N Kroeger","year":"2014","unstructured":"Kroeger N, Choueiri TK, Lee JL, Bjarnason GA, Knox JJ, Mackenzie MJ et al. Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. Eur Urol 2014; 65: 1086\u20131092.","journal-title":"Eur Urol"},{"key":"BFonc20164_CR9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115\u2013124.","journal-title":"N Engl J Med"},{"key":"BFonc20164_CR10","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","volume":"22","author":"MB Atkins","year":"2004","unstructured":"Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22: 909\u2013918.","journal-title":"J Clin Oncol"},{"key":"BFonc20164_CR11","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","volume":"370","author":"B Escudier","year":"2007","unstructured":"Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103\u20132111.","journal-title":"Lancet"},{"key":"BFonc20164_CR12","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/S1470-2045(09)70240-2","volume":"10","author":"BI Rini","year":"2009","unstructured":"Rini BI, Atkins MB . Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 2009; 10: 992\u20131000.","journal-title":"Lancet Oncol"},{"key":"BFonc20164_CR13","doi-asserted-by":"publisher","first-page":"44955","DOI":"10.1074\/jbc.M407617200","volume":"279","author":"H Zhang","year":"2004","unstructured":"Zhang H, Zhang R, Luo Y, D'Alessio A, Pober JS, Min W . AIP1\/DAB2IP, a novel member of the Ras-GAP family, transduces TRAF2-induced ASK1-JNK activation. J Biol Chem 2004; 279: 44955\u201344965.","journal-title":"J Biol Chem"},{"key":"BFonc20164_CR14","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/nm.2100","volume":"16","author":"J Min","year":"2010","unstructured":"Min J, Zaslavsky A, Fedele G, McLaughlin SK, Reczek EE, De Raedt T et al. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med 2010; 16: 286\u2013294.","journal-title":"Nat Med"},{"key":"BFonc20164_CR15","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1158\/1078-0432.CCR-13-0954","volume":"19","author":"K Wu","year":"2013","unstructured":"Wu K, Xie D, Zou Y, Zhang T, Pong RC, Xiao G et al. The mechanism of DAB2IP in chemoresistance of prostate cancer cells. Clin Cancer Res 2013; 19: 4740\u20134749.","journal-title":"Clin Cancer Res"},{"key":"BFonc20164_CR16","doi-asserted-by":"publisher","first-page":"19878","DOI":"10.1073\/pnas.0908458106","volume":"106","author":"D Xie","year":"2009","unstructured":"Xie D, Gore C, Zhou J, Pong RC, Zhang H, Yu L et al. DAB2IP coordinates both PI3K-Akt and ASK1 pathways for cell survival and apoptosis. Proc Natl Acad Sci USA 2009; 106: 19878\u201319883.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc20164_CR17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.jhep.2010.06.036","volume":"54","author":"DF Calvisi","year":"2011","unstructured":"Calvisi DF, Ladu S, Conner EA, Seo D, Hsieh JT, Factor VM et al. Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer. J Hepatol 2011; 54: 311\u2013319.","journal-title":"J Hepatol"},{"key":"BFonc20164_CR18","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1006\/geno.2002.6739","volume":"79","author":"H Chen","year":"2002","unstructured":"Chen H, Pong RC, Wang Z, Hsieh JT . Differential regulation of the human gene DAB2IP in normal and malignant prostatic epithelia: cloning and characterization. Genomics 2002; 79: 573\u2013581.","journal-title":"Genomics"},{"key":"BFonc20164_CR19","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1074\/jbc.M208230200","volume":"278","author":"H Chen","year":"2003","unstructured":"Chen H, Toyooka S, Gazdar AF, Hsieh JT . Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines. J Biol Chem 2003; 278: 3121\u20133130.","journal-title":"J Biol Chem"},{"key":"BFonc20164_CR20","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jhep.2006.11.012","volume":"46","author":"GH Qiu","year":"2007","unstructured":"Qiu GH, Xie H, Wheelhouse N, Harrison D, Chen GG, Salto-Tellez M et al. Differential expression of hDAB2IPA and hDAB2IPB in normal tissues and promoter methylation of hDAB2IPA in hepatocellular carcinoma. J Hepatol 2007; 46: 655\u2013663.","journal-title":"J Hepatol"},{"key":"BFonc20164_CR21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/ki.1994.6","volume":"45","author":"MJ Ryan","year":"1994","unstructured":"Ryan MJ, Johnson G, Kirk J, Fuerstenberg SM, Zager RA, Torok-Storb B . HK-2: an immortalized proximal tubule epithelial cell line from normal adult human kidney. Kidney Int 1994; 45: 48\u201357.","journal-title":"Kidney Int"},{"key":"BFonc20164_CR22","first-page":"243","volume":"61","author":"RL Omeir","year":"2011","unstructured":"Omeir RL, Teferedegne B, Foseh GS, Beren JJ, Snoy PJ, Brinster LR et al. Heterogeneity of the tumorigenic phenotype expressed by Madin-Darby canine kidney cells. Comp Med 2011; 61: 243\u2013250.","journal-title":"Comp Med"},{"key":"BFonc20164_CR23","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1128\/MCB.18.1.629","volume":"18","author":"AB Niculescu 3rd","year":"1998","unstructured":"Niculescu AB 3rd, Chen X, Smeets M, Hengst L, Prives C, Reed SI . Effects of p21(Cip1\/Waf1) at both the G1\/S and the G2\/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol 1998; 18: 629\u2013643.","journal-title":"Mol Cell Biol"},{"key":"BFonc20164_CR24","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ccr.2007.02.006","volume":"11","author":"JD Gordan","year":"2007","unstructured":"Gordan JD, Bertout JA, Hu CJ, Diehl JA, Simon MC . HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 2007; 11: 335\u2013347.","journal-title":"Cancer Cell"},{"key":"BFonc20164_CR25","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1093\/carcin\/bgl143","volume":"28","author":"T Shinojima","year":"2007","unstructured":"Shinojima T, Oya M, Takayanagi A, Mizuno R, Shimizu N, Murai M . Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha. Carcinogenesis 2007; 28: 529\u2013536.","journal-title":"Carcinogenesis"},{"key":"BFonc20164_CR26","doi-asserted-by":"publisher","first-page":"10385","DOI":"10.1073\/pnas.1105680108","volume":"108","author":"O Laptenko","year":"2011","unstructured":"Laptenko O, Beckerman R, Freulich E, Prives C . p53 binding to nucleosomes within the p21 promoter in vivo leads to nucleosome loss and transcriptional activation. Proc Natl Acad Sci USA 2011; 108: 10385\u201310390.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc20164_CR27","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.eururo.2009.09.002","volume":"56","author":"G Di Lorenzo","year":"2009","unstructured":"Di Lorenzo G, Autorino R, Sternberg CN . Metastatic renal cell carcinoma: recent advances in the targeted therapy era. Eur Urol 2009; 56: 959\u2013971.","journal-title":"Eur Urol"},{"key":"BFonc20164_CR28","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1038\/sj.emboj.7601166","volume":"25","author":"D Shahbazian","year":"2006","unstructured":"Shahbazian D, Roux PP, Mieulet V, Cohen MS, Raught B, Taunton J et al. The mTOR\/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J 2006; 25: 2781\u20132791.","journal-title":"EMBO J"},{"key":"BFonc20164_CR29","first-page":"3065","volume":"118","author":"A Carracedo","year":"2008","unstructured":"Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008; 118: 3065\u20133074.","journal-title":"J Clin Invest"},{"key":"BFonc20164_CR30","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1038\/onc.2010.626","volume":"30","author":"V Serra","year":"2011","unstructured":"Serra V, Scaltriti M, Prudkin L, Eichhorn PJ, Ibrahim YH, Chandarlapaty S et al. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 2011; 30: 2547\u20132557.","journal-title":"Oncogene"},{"key":"BFonc20164_CR31","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1172\/JCI66343","volume":"123","author":"V Serra","year":"2013","unstructured":"Serra V, Eichhorn PJ, Garcia-Garcia C, Ibrahim YH, Prudkin L, Sanchez G et al. RSK3\/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J Clin Invest 2013; 123: 2551\u20132563.","journal-title":"J Clin Invest"},{"key":"BFonc20164_CR32","doi-asserted-by":"publisher","first-page":"4268","DOI":"10.1016\/j.febslet.2010.09.010","volume":"584","author":"F Das","year":"2010","unstructured":"Das F, Ghosh-Choudhury N, Kasinath BS, Choudhury GG . TGFbeta enforces activation of eukaryotic elongation factor-2 (eEF2) via inactivation of eEF2 kinase by p90 ribosomal S6 kinase (p90Rsk) to induce mesangial cell hypertrophy. FEBS Lett 2010; 584: 4268\u20134272.","journal-title":"FEBS Lett"},{"key":"BFonc20164_CR33","doi-asserted-by":"publisher","first-page":"14056","DOI":"10.1074\/jbc.M700906200","volume":"282","author":"PP Roux","year":"2007","unstructured":"Roux PP, Shahbazian D, Vu H, Holz MK, Cohen MS, Taunton J et al. RAS\/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem 2007; 282: 14056\u201314064.","journal-title":"J Biol Chem"},{"key":"BFonc20164_CR34","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1002\/ijc.28236","volume":"133","author":"E Martinelli","year":"2013","unstructured":"Martinelli E, Troiani T, D'Aiuto E, Morgillo F, Vitagliano D, Capasso A et al. Antitumor activity of pimasertib, a selective MEK 1\/2 inhibitor, in combination with PI3K\/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. Int J Cancer 2013; 133: 2089\u20132101.","journal-title":"Int J Cancer"},{"key":"BFonc20164_CR35","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1093\/jnci\/djm250","volume":"99","author":"D Duggan","year":"2007","unstructured":"Duggan D, Zheng SL, Knowlton M, Benitez D, Dimitrov L, Wiklund F et al. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst 2007; 99: 1836\u20131844.","journal-title":"J Natl Cancer Inst"},{"key":"BFonc20164_CR36","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1158\/1078-0432.CCR-03-0236","volume":"10","author":"H Dote","year":"2004","unstructured":"Dote H, Toyooka S, Tsukuda K, Yano M, Ouchida M, Doihara H et al. Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in breast cancer. Clin Cancer Res 2004; 10: 2082\u20132089.","journal-title":"Clin Cancer Res"},{"key":"BFonc20164_CR37","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1111\/j.1440-1746.2011.07049.x","volume":"27","author":"X Zhang","year":"2012","unstructured":"Zhang X, Li N, Li X, Zhao W, Qiao Y, Liang L et al. Low expression of DAB2IP contributes to malignant development and poor prognosis in hepatocellular carcinoma. J Gastroenterol Hepatol 2012; 27: 1117\u20131125.","journal-title":"J Gastroenterol Hepatol"},{"key":"BFonc20164_CR38","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/ijc.20531","volume":"113","author":"M Yano","year":"2005","unstructured":"Yano M, Toyooka S, Tsukuda K, Dote H, Ouchida M, Hanabata T et al. Aberrant promoter methylation of human DAB2 interactive protein (hDAB2IP) gene in lung cancers. Int J Cancer 2005; 113: 59\u201366.","journal-title":"Int J Cancer"},{"key":"BFonc20164_CR39","doi-asserted-by":"publisher","first-page":"22437","DOI":"10.1074\/jbc.M501379200","volume":"280","author":"H Chen","year":"2005","unstructured":"Chen H, Tu SW, Hsieh JT . Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. J Biol Chem 2005; 280: 22437\u201322444.","journal-title":"J Biol Chem"},{"key":"BFonc20164_CR40","doi-asserted-by":"publisher","first-page":"4048","DOI":"10.1158\/1078-0432.CCR-12-0399","volume":"18","author":"M Smits","year":"2012","unstructured":"Smits M, van Rijn S, Hulleman E, Biesmans D, van Vuurden DG, Kool M et al. EZH2-regulated DAB2IP is a medulloblastoma tumor suppressor and a positive marker for survival. Clin Cancer Res 2012; 18: 4048\u20134058.","journal-title":"Clin Cancer Res"},{"key":"BFonc20164_CR41","doi-asserted-by":"publisher","first-page":"12622","DOI":"10.1074\/jbc.M110568200","volume":"277","author":"Z Wang","year":"2002","unstructured":"Wang Z, Tseng CP, Pong RC, Chen H, McConnell JD, Navone N et al. The mechanism of growth-inhibitory effect of DOC-2\/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2\/DAB2. J Biol Chem 2002; 277: 12622\u201312631.","journal-title":"J Biol Chem"},{"key":"BFonc20164_CR42","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/JCI7319","volume":"104","author":"H Onda","year":"1999","unstructured":"Onda H, Lueck A, Marks PW, Warren HB, Kwiatkowski DJ . Tsc2(+\/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J Clin Invest 1999; 104: 687\u2013695.","journal-title":"J Clin Invest"},{"key":"BFonc20164_CR43","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1073\/pnas.0710887105","volume":"105","author":"AM Abukhdeir","year":"2008","unstructured":"Abukhdeir AM, Vitolo MI, Argani P, De Marzo AM, Karakas B, Konishi H et al. Tamoxifen-stimulated growth of breast cancer due to p21 loss. Proc Natl Acad Sci USA 2008; 105: 288\u2013293.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc20164_CR44","doi-asserted-by":"publisher","first-page":"9042","DOI":"10.1073\/pnas.160016897","volume":"97","author":"S Cariou","year":"2000","unstructured":"Cariou S, Donovan JC, Flanagan WM, Milic A, Bhattacharya N, Slingerland JM . Down-regulation of p21WAF1\/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc Natl Acad Sci USA 2000; 97: 9042\u20139046.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc20164_CR45","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1158\/0008-5472.CAN-09-3965","volume":"70","author":"D Huang","year":"2010","unstructured":"Huang D, Ding Y, Zhou M, Rini BI, Petillo D, Qian CN et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 2010; 70: 1063\u20131071.","journal-title":"Cancer Res"},{"key":"BFonc20164_CR46","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1128\/MCB.00601-09","volume":"30","author":"LA Julien","year":"2010","unstructured":"Julien LA, Carriere A, Moreau J, Roux PP . mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol Cell Biol 2010; 30: 908\u2013921.","journal-title":"Mol Cell Biol"},{"key":"BFonc20164_CR47","doi-asserted-by":"publisher","first-page":"D141","DOI":"10.1093\/nar\/gkn879","volume":"37","author":"JR Cole","year":"2009","unstructured":"Cole JR, Wang Q, Cardenas E, Fish J, Chai B, Farris RJ et al. The Ribosomal Database Project: improved alignments and new tools for rRNA analysis. Nucleic Acids Res 2009; 37: D141\u2013D145.","journal-title":"Nucleic Acids Res"},{"key":"BFonc20164_CR48","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2: 401\u2013404.","journal-title":"Cancer Discov"},{"key":"BFonc20164_CR49","doi-asserted-by":"publisher","first-page":"7252","DOI":"10.1158\/1078-0432.CCR-04-0713","volume":"10","author":"RL Camp","year":"2004","unstructured":"Camp RL, Dolled-Filhart M, Rimm DL . X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004; 10: 7252\u20137259.","journal-title":"Clin Cancer Res"},{"key":"BFonc20164_CR50","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC . Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010; 70: 440\u2013446.","journal-title":"Cancer Res"}],"updated-by":[{"DOI":"10.1038\/s41388-026-03721-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000}}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/onc20164.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc20164","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc20164.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T07:58:02Z","timestamp":1772611082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc20164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,15]]},"references-count":50,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2016,9,1]]}},"alternative-id":["BFonc20164"],"URL":"https:\/\/doi.org\/10.1038\/onc.2016.4","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,15]]},"assertion":[{"value":"22 June 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41388-026-03721-z","URL":"https:\/\/doi.org\/10.1038\/s41388-026-03721-z","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}